Running Point Capital Advisors’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Running Point Capital Advisors’s Portfolio LJPC Stock Details LJPC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,000	Closed	-$32K	–	243
2022 Q2	$32K	Hold	10,000	–	–	0.02%	172
2022 Q1	$43K	Buy	+10,000	New	+$43.6K	0.03%	163

Running Point Capital Advisors's LJPC Position: Q3 2022 in Review

Running Point Capital Advisors sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 10,000 shares — an estimated $32K sold.

Running Point Capital Advisors first reported a position in LJPC in Q1 2022 and held it in 2 quarters. The position peaked at $43K in Q1 2022. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.

Running Point Capital Advisors reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
Running Point Capital Advisors sold 10,000 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $32K.
Running Point Capital Advisors first reported a position in La Jolla Pharmaceutical Company in Q1 2022 and held it in 2 quarters.
Running Point Capital Advisors's La Jolla Pharmaceutical Company position peaked at $43K in Q1 2022.
0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.

Based on Running Point Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.